Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
April 09, 2024 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
April 03, 2024 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
March 21, 2024 08:00 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
February 29, 2024 16:05 ET
|
Lisata Therapeutics, Inc.
Phase 2b ASCEND trial fully enrolled and on track for top-line data in fourth quarter of 2024 Company affirms projection of operational funds into early 2026 Conference call scheduled for today at...
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
February 22, 2024 08:00 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics to Present at BIO CEO & Investor Conference
February 20, 2024 08:00 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme
January 17, 2024 08:00 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
January 04, 2024 08:00 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
December 12, 2023 08:00 ET
|
Lisata Therapeutics, Inc.
Enrollment completed approximately six months earlier than originally projected Top-line placebo-controlled, blinded, randomized data now expected in the fourth quarter of 2024 BASKING RIDGE, N.J.,...
Lisata Therapeutics to Present at NobleCon19 Investor Conference
November 28, 2023 16:05 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...